

# Alexander C Fanaroff

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6731187/publications.pdf>

Version: 2024-02-01

79  
papers

1,608  
citations

331670

21  
h-index

315739

38  
g-index

84  
all docs

84  
docs citations

84  
times ranked

2387  
citing authors

#	ARTICLE	IF	CITATIONS
1	Seeking patient-centered trial outcomes: The case for days alive out of hospital. American Heart Journal, 2022, 248, 172-174.	2.7	3
2	Racial, Ethnic, and Socioeconomic Disparities in Access to Transcatheter Aortic Valve Replacement Within Major Metropolitan Areas. JAMA Cardiology, 2022, 7, 150.	6.1	37
3	Economic Considerations in Access to Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121011489.	3.9	8
4	Rural-Urban Disparities in Cardiovascular Outcomes. Journal of the American College of Cardiology, 2022, 79, 280-282.	2.8	4
5	Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention. Journal of the American College of Cardiology, 2022, 79, 417-427.	2.8	12
6	Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease. European Heart Journal Supplements, 2022, 24, A19-A31.	0.1	6
7	Epidemiology and Outcomes of Patients Readmitted to the Intensive Care Unit After Cardiac Intensive Care Unit Admission. American Journal of Cardiology, 2022, 170, 138-146.	1.6	0
8	Independence of clinical events committees: A consensus statement from clinical research organizations. American Heart Journal, 2022, 248, 120-129.	2.7	2
9	Recognising acute coronary syndrome. BMJ, The, 2022, 377, e069591.	6.0	5
10	Percutaneous Coronary Intervention in Acute Coronary Syndrome and Cardiogenic Shock. JACC: Cardiovascular Interventions, 2022, 15, 887-889.	2.9	2
11	Association between intensive care unit utilization for patients with non-“ST-segment elevation myocardial infarction and patient experience. American Heart Journal, 2021, 231, 32-35.	2.7	0
12	Anticoagulation dosing in atherosclerotic cardiovascular disease: Is less more?. European Journal of Internal Medicine, 2021, 83, 8-9.	2.2	0
13	Oral anticoagulant use in patients with atrial fibrillation and mitral valve repair. American Heart Journal, 2021, 232, 1-9.	2.7	6
14	Antithrombotic Regimens in Low-Risk Patients Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2021, 14, e010331.	3.9	0
15	Electronic Health Record Integration of Predictive Analytics to Select High-Risk Stable Patients With Non-“ST-Segment“Elevation Myocardial Infarction for Intensive Care Unit Admission. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007602.	2.2	4
16	Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US. JAMA Network Open, 2021, 4, e216139.	5.9	187
17	Association of Health Insurance Payer Type and Outcomes After Durable Left Ventricular Assist Device Implantation: An Analysis of the STS-INTERMACS Registry. Circulation: Heart Failure, 2021, 14, e008277.	3.9	1
18	Adding Precision to Defining Bleeding and Ischemic Risk With PCI in Cancer Patients. JACC: Cardiovascular Interventions, 2021, 14, 1106-1108.	2.9	1

#	ARTICLE	IF	CITATIONS
19	Reporting of Percutaneous Coronary Interventions Site-Specific Mortality—Reply. JAMA Cardiology, 2021, 6, 1344.	6.1	0
20	Lack of Association Between Percutaneous Coronary Intervention and Transcatheter Aortic Valve Replacement Outcomes in New York Hospitals. Circulation: Cardiovascular Interventions, 2021, 14, e010750.	3.9	0
21	Geographic and Socioeconomic Disparities in Major Lower Extremity Amputation Rates in Metropolitan Areas. Journal of the American Heart Association, 2021, 10, e021456.	3.7	42
22	Socioeconomic and Geographic Characteristics of Hospitals Establishing Transcatheter Aortic Valve Replacement Programs, 2012–2018. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e008260.	2.2	27
23	Comparison of Patients Undergoing Percutaneous Coronary Intervention in Contemporary U.S. Practice With ISCHEMIA Trial Population. JACC: Cardiovascular Interventions, 2021, 14, 2344-2349.	2.9	11
24	Hospital-Level Percutaneous Coronary Intervention Performance With Simulated Risk Avoidance. Journal of the American College of Cardiology, 2021, 78, 2213-2217.	2.8	1
25	1 Month of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2021, 78, 2073-2075.	2.8	0
26	Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US. JAMA Health Forum, 2021, 2, e214182.	2.2	58
27	The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Progress in Cardiovascular Diseases, 2021, 69, 11-17.	3.1	1
28	Atrial Fibrillation and Coronary Artery Disease: A Long-Term Perspective on the Need for Combined Antithrombotic Therapy. Circulation: Cardiovascular Interventions, 2021, 14, e011232.	3.9	9
29	Radial Access for Peripheral Interventions. Interventional Cardiology Clinics, 2020, 9, 53-61.	0.4	5
30	Anticoagulation in COVID-19. Journal of the American College of Cardiology, 2020, 76, 1827-1829.	2.8	10
31	Randomized Trials Versus Common Sense and Clinical Observation. Journal of the American College of Cardiology, 2020, 76, 580-589.	2.8	50
32	Antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: balance best with double antithrombotic therapy. European Heart Journal, 2020, 41, 4505-4507.	2.2	3
33	Association Between 90-Minute Door-to-Balloon Time, Selective Exclusion of Myocardial Infarction Cases, and Access Site Choice. Circulation: Cardiovascular Interventions, 2020, 13, e009179.	3.9	9
34	Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006182.	2.2	5
35	Association Between Intensive Care Unit Usage and Long-Term Medication Adherence, Mortality, and Readmission Among Initially Stable Patients With Non-ST-Elevation Myocardial Infarction. Journal of the American Heart Association, 2020, 9, e015179.	3.7	4
36	Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill. JAMA Cardiology, 2020, 5, 532.	6.1	8

#	ARTICLE	IF	CITATIONS
37	Clinical outcomes and need for intensive care after non-ST-segment-elevation myocardial infarction. European Journal of Internal Medicine, 2020, 76, 58-63.	2.2	8
38	Incidence, Temporal Trends, and Associated Outcomes of Vascular and Bleeding Complications in Patients Undergoing Transfemoral Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2020, 13, e008227.	3.9	49
39	Methods for safety and endpoint ascertainment: identification of adverse events through scrutiny of negatively adjudicated events. Trials, 2020, 21, 323.	1.6	3
40	Levels of evidence supporting drug, device, and other recommendations in the American Heart Association/American College of Cardiology guidelines. American Heart Journal, 2020, 226, 4-12.	2.7	6
41	New Approaches to Conducting Randomized Controlled Trials. Journal of the American College of Cardiology, 2020, 75, 556-559.	2.8	17
42	Patient and Staff Perceptions of Universal Severe Acute Respiratory Syndrome Coronavirus 2 Screening Prior to Cardiac Catheterization and Electrophysiology Laboratory Procedures. Circulation: Cardiovascular Interventions, 2020, 13, e009975.	3.9	1
43	Current landscape of hybrid revascularization: A report from the NCDR CathPCI Registry. American Heart Journal, 2019, 215, 167-177.	2.7	17
44	High-quality evidence to inform clinical practice. Lancet, The, 2019, 394, 633-634.	13.7	10
45	Hospital participation in clinical trials for patients with acute myocardial infarction: Results from the National Cardiovascular Data Registry. American Heart Journal, 2019, 214, 184-193.	2.7	8
46	Physiologic Assessment of Stent Deployment. Circulation: Cardiovascular Interventions, 2019, 12, e007955.	3.9	0
47	Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018. JAMA - Journal of the American Medical Association, 2019, 321, 1069.	7.4	144
48	Size of Anterior Wall Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention in United States Versus Europe/Australia Versus India (from the CRISP-AMI Randomized) Tj ETQq0 0 0 1gBT /Overclock 10 Tf	13.7	10
49	Relationship Between Optimism and Outcomes in Patients With Chronic Angina Pectoris. American Journal of Cardiology, 2019, 123, 1399-1405.	1.6	5
50	Relationship Between Operator Volume and Long-Term Outcomes After Percutaneous Coronary Intervention. Circulation, 2019, 139, 458-472.	1.6	43
51	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. Circulation, 2019, 139, 863-873.	1.6	18
52	Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation. Annual Review of Medicine, 2019, 70, 61-75.	12.2	9
53	Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS (Treatment With ADP Receptor) Tj ETQq1 1 0.784314 rgBT /Overclock 10 Tf	3.7	2
54	Stroke prevention in atrial fibrillation: re-defining "real-world data"™ within the broader data universe. European Heart Journal, 2018, 39, 2932-2941.	2.2	22

#	ARTICLE	IF	CITATIONS
55	An Observational Study of the Association of Video- Versus Text-Based Informed Consent With Multicenter Trial Enrollment. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004675.	2.2	20
56	Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004755.	2.2	51
57	A Path Forward for Regenerative Medicine. <i>Circulation Research</i> , 2018, 123, 495-505.	4.5	6
58	Association Between Cardiac Catheterization Laboratory Pre-Activation and Reperfusion Timing Metrics and Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1837-1847.	2.9	29
59	Risk Score to Predict Need for Intensive Care in Initially Hemodynamically Stable Adults With Non-“ST-Segment” Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	26
60	Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2304-2313.	2.8	14
61	Outcomes of PCI in Relation to Procedural Characteristics and Operator Volumes in the United States. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2913-2924.	2.8	104
62	PATTERNS OF ANGINA AND ANTIANGINAL MEDICATION USE AMONG PATIENTS FOLLOWING MI TREATED WITH PCI: INSIGHTS FROM TRANSLATE-ACS. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1.	2.8	0
63	ANTIPLATELET THERAPY CHANGES FOR MI PATIENTS WITH RECURRENT ISCHEMIC EVENTS: INSIGHTS INTO CONTEMPORARY PRACTICE FROM THE TRANSLATE-ACS STUDY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 24.	2.8	1
64	PERIPHERAL ARTERY DISEASE AND TRANSCATHETER AORTIC VALVE REPLACEMENT OUTCOMES: A REPORT FROM THE STS/TVT REGISTRY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 991.	2.8	1
65	Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. <i>International Journal of Cardiology</i> , 2017, 241, 87-96.	1.7	24
66	Peripheral Artery Disease and Transcatheter Aortic Valve Replacement Outcomes. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	79
67	Management of Persistent Angina After Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	23
68	Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long-Term Follow-Up After Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	14
69	Intensive Care Unit Utilization and Mortality Among Medicare Patients Hospitalized With Non-“ST-Segment Elevation Myocardial Infarction. <i>JAMA Cardiology</i> , 2017, 2, 36.	6.1	31
70	Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease. <i>Drug Safety</i> , 2016, 39, 715-727.	3.2	12
71	Antiplatelet Therapy in Percutaneous Coronary Intervention. <i>Interventional Cardiology Clinics</i> , 2016, 5, 221-237.	0.4	5
72	Simplified Predictive Instrument to Rule Out Acute Coronary Syndromes in a High-Risk Population. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	1

#	ARTICLE	IF	CITATIONS
73	Acute Coronary Syndrome. JAMA - Journal of the American Medical Association, 2015, 314, 1990.	7.4	9
74	Conundrums for Atrial Fibrillation Management in Older Adults. Current Geriatrics Reports, 2015, 4, 368-376.	1.1	0
75	Does This Patient With Chest Pain Have Acute Coronary Syndrome?. JAMA - Journal of the American Medical Association, 2015, 314, 1955.	7.4	170
76	Patient Selection for Advanced Heart Failure Therapy Referral. Critical Pathways in Cardiology, 2014, 13, 1-5.	0.5	17
77	The impact of a measurement and feedback intervention on blood pressure control in ambulatory cardiology practice. American Heart Journal, 2014, 167, 466-471.	2.7	4
78	Kalirin Promotes Neointimal Hyperplasia by Activating Rac in Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 702-708.	2.4	40
79	G Protein-Coupled Receptor Kinase-5 Attenuates Atherosclerosis by Regulating Receptor Tyrosine Kinases and 7-Transmembrane Receptors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 308-316.	2.4	38